Treats relapsing forms of multiple sclerosis (MS). ANDA 210436, held by Sola Pharms. Dimethyl Fumarate.
As of Nov 16, 2026, ANDA 210436 (Dimethyl Fumarate), held by Sola Pharms, was first approved by FDA on Mar 26, 2021, with 2 approved supplements and 0 published complete response letters.
Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 26, 2021 | Original application | Approved | None posted |
| Dimethyl Fumarate120MG · capsule, delayed release;oral | Dimethyl Fumarate | Rx |
| Dimethyl Fumarate240MG · capsule, delayed release;oral | Dimethyl Fumarate | Rx |
| Dec 18, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 18, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 26, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters